` CRDL (Cardiol Therapeutics Inc) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

CRDL
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, CRDL has underperformed S&P TSX Composite Index (Canada), delivering a return of -23% compared to the S&P TSX Composite Index (Canada)'s +25% growth.

Stocks Performance
CRDL vs S&P TSX Composite Index (Canada)

Loading
CRDL
S&P TSX Composite Index (Canada)
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CRDL vs S&P TSX Composite Index (Canada)

Loading
CRDL
S&P TSX Composite Index (Canada)
Difference
www.alphaspread.com

Performance By Year
CRDL vs S&P TSX Composite Index (Canada)

Loading
CRDL
S&P TSX Composite Index (Canada)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Cardiol Therapeutics Inc vs Peers

S&P TSX Composite Index (Canada)
CRDL
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Cardiol Therapeutics Inc
Glance View

Market Cap
146.3m CAD
Industry
Pharmaceuticals

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

CRDL Intrinsic Value
2.8 CAD
Undervaluation 47%
Intrinsic Value
Price
Back to Top